object
respiratori
syncyti
viru
pathogen
frequent
involv
nosocomi
outbreak
although
sever
studi
report
nosocomi
outbreak
neonat
intens
care
unit
molecular
epidemiolog
data
scarc
author
describ
two
consecut
respiratori
syncyti
viru
outbreak
caus
genotyp
neonat
intens
care
unit
paulo
brazil
method
prospect
search
respiratori
syncyti
viru
perform
diagnos
index
case
four
symptomat
newborn
neonat
intens
care
unit
nasopharyng
aspir
sampl
patient
neonat
intens
care
unit
test
respiratori
virus
use
realtim
revers
transcriptas
polymeras
chain
reaction
genotyp
perform
use
nucleotid
sequenc
result
may
august
two
differ
outbreak
detect
neonat
intens
care
unit
total
infant
infect
respiratori
syncyti
virusa
ten
pleas
cite
articl
silva
dg
almeida
fj
arnoni
mv
mimica
mj
jarovski
et
al
first
report
two
consecut
respiratori
syncyti
viru
outbreak
novel
genotyp
neonat
intens
care
unit
j
pediatr
rio
j
byncnd
licens
http
lactent
era
de
dia
peso
ao
nascer
foi
de
g
e
idad
gestacion
de
semana
fator
de
risco
pulmonar
e
prematuridad
estavam
present
em
e
do
no
grupo
e
respectivament
total
do
lactent
eram
e
necessitaram
de
foram
detectada
durant
os
surto
em
unidad
de
terapia
intensiva
neonat
que
desenvolvem
sintoma
abrupto
devem
ser
testado
para
especialment
sincici
mesmo
na
de
sintoma
grave
de
sincici
pode
prevenir
nosocomi
de
medida
de
control
de
um
melhor
entendimento
da
epidemiologia
molecular
sincici
essenci
para
desenvolvimento
de
nova
vacina
e
droga
antivirai
contra
sincici
genotyp
respect
mean
age
infant
day
mean
birth
weight
g
mean
gestat
age
week
risk
factor
heart
diseas
lung
diseas
prematur
present
infant
group
respect
total
infant
asymptomat
requir
mechan
ventil
coinfect
detect
outbreak
conclus
infant
neonat
intens
care
unit
develop
abrupt
respiratori
symptom
test
respiratori
virus
especi
respiratori
syncyti
viru
even
absenc
sever
symptom
respiratori
syncyti
viru
detect
prevent
nosocomi
transmiss
infect
control
measur
better
understand
respiratori
syncyti
viru
molecular
epidemiolog
essenti
develop
new
vaccin
antivir
drug
respiratori
syncyti
viru
sociedad
brasileira
de
pediatria
publish
elsevi
editora
ltda
open
access
articl
cc
byncnd
licens
http
creativecommonsorglicensesbyncnd
respiratori
syncyti
viru
rsv
infect
potenti
lifethreaten
infant
particularli
prematur
infant
chronic
lung
diseas
congenit
heart
diseas
rsv
caus
sever
outbreak
neonat
intens
care
unit
nicu
lead
substanti
morbid
mortal
preterm
infant
well
increas
financi
cost
convent
infect
control
method
hand
hygien
patient
isol
cohort
recommend
howev
procedur
may
supplement
use
palivizumab
synagi
medimmun
inc
gaithersburg
md
usa
rsv
divid
type
rsva
b
rsvb
base
antigen
differ
deriv
glycoprotein
g
f
categor
subtyp
base
variabl
domain
attach
g
protein
type
often
tend
domin
associ
enhanc
diseas
sever
reinfect
rsv
common
occurr
mani
genotyp
circul
concomitantli
variabl
might
contribut
abil
viru
caus
yearli
outbreak
sever
diseas
furthermor
previou
report
rsv
infect
outbreak
describ
vari
degre
diseas
sever
control
presenc
differ
viral
genotyp
may
differ
virul
brazil
pauciti
data
neonat
regard
molecular
epidemiolog
rsv
emerg
novel
viral
strain
although
circul
rsv
genotyp
alreadi
describ
impact
cours
rsv
infect
nicu
possibl
outbreak
remain
determin
author
report
two
consecut
rsv
outbreak
caus
differ
genotyp
brazilian
nicu
sinc
earli
detect
case
crucial
contain
viral
transmiss
studi
aim
clarifi
import
molecular
detect
type
well
infect
control
measur
challeng
set
averag
differ
healthcar
profession
physic
contact
babi
nicu
daili
six
neonat
hospitalist
eight
neonat
fellow
four
pediatr
resid
four
medic
school
graduat
student
six
nurs
practition
nurs
technician
five
respiratori
therapist
hand
clean
replac
person
cloth
apron
provid
hospit
parent
allow
visit
ward
particip
room
rsv
po
iti
infant
room
rsv
ne
gati
infant
room
rsv
negati
nfant
room
rsv
negati
nfant
without
previ
ou
expo
ure
neonat
unit
upper
respiratori
tract
infect
defin
cough
rhinorrhea
present
bronchiol
diagnosi
made
base
follow
symptom
tachypnea
wheez
cough
crepitu
andor
nasal
flare
identif
symptomat
infant
confirm
rsv
infect
nasopharyng
aspir
npa
sampl
collect
infant
hospit
nicu
npa
surveil
repeat
twice
week
patient
sampl
sent
institut
biomed
scienc
univers
paulo
viral
rna
extract
automat
nuclisen
easymag
extractor
biomerieux
inc
durham
usa
accord
manufactur
instruct
realtim
revers
transcript
rrt
polymeras
chain
reaction
pcr
perform
agpathid
onestep
rrtpcr
kit
realtim
pcr
system
appli
biosystem
foster
citi
usa
identifi
pathogen
respons
outbreak
rrtpcr
perform
noninfluenza
viru
rrtpcr
panel
kit
detect
respiratori
virus
rsv
group
group
b
human
metapneumoviru
adenoviru
human
coronavirus
hcovhku
human
parainfluenza
viru
type
human
bocaviru
human
enteroviru
human
rhinoviru
provid
center
diseas
control
prevent
cdc
atlanta
ga
usa
commerci
primer
probe
influenza
b
invitrogen
carlsbad
usa
posit
qpcr
sampl
amplifi
convent
twostep
pcr
dna
sequenc
cdna
synthes
use
superscript
iii
kit
appli
biosystem
foster
citi
usa
accord
manufactur
instruct
analys
second
hypervari
region
g
protein
gene
carri
use
pcr
primer
fw
fvab
rev
mixtur
contain
l
cdna
l
pcr
buffer
mm
dntp
pmol
primer
u
platinum
taq
dna
polymeras
invitrogen
carlsbad
usa
nucleasefre
water
final
volum
l
second
step
seminest
pcr
perform
neg
sampl
first
pcr
use
forward
primer
fwd
revers
primer
rev
condit
use
convent
pcr
amplif
perform
use
geneamp
pcr
system
thermocycl
appli
biosystem
foster
citi
usa
use
follow
program
c
min
follow
cycl
consist
c
c
c
final
min
extens
c
amplifi
product
analyz
use
agaros
gel
electrophoresi
visual
ultraviolet
light
stain
ethidium
bromid
amplifi
product
gene
g
bp
produc
use
convent
pcr
seminest
pcr
consecut
purifi
use
exosapit
affymetrix
inc
santa
clara
usa
submit
cycl
sequenc
reaction
sanger
use
fluoresc
dye
termin
kit
primer
fv
dna
sequenc
appli
biosystem
foster
citi
usa
strand
amplif
product
sequenc
least
twice
sequenc
edit
align
phylogenet
analys
perform
megalign
softwar
dnastar
inc
madison
usa
standard
publish
sequenc
subgroup
download
genbank
http
wwwncbinlmnihgovgenbank
refer
differ
lineag
genotyp
studi
approv
local
research
ethic
committe
index
case
involv
preterm
boy
week
gestat
age
birth
weight
g
hospit
sinc
birth
prematur
bronchopulmonari
dysplasia
wean
oxygen
supplement
intermedi
care
unit
cough
runni
nose
fever
start
respiratori
failur
develop
rapidli
requir
mv
five
day
later
five
infant
nicu
develop
respiratori
symptom
therefor
outbreak
declar
fig
day
npa
sampl
collect
patient
nicu
rrtpcr
respiratori
viru
detect
ten
infant
infect
rsv
three
share
ward
index
case
attack
rate
one
fatal
occur
cfr
howev
death
attribut
rsv
infect
sinc
patient
present
respiratori
symptom
congenit
pulmonari
hypoplasia
consid
caus
death
addit
inform
provid
tabl
contact
respiratori
precaut
immedi
implement
infant
nicu
separ
three
differ
cohort
rsvposit
infant
place
ward
contact
respiratori
precaut
rsvneg
infant
previou
contact
rsvposit
infant
place
ward
contact
precaut
rsvneg
infant
never
contact
rsvposit
patient
place
ward
healthcar
staff
also
divid
across
ward
intern
rotat
schedul
suspend
fifti
npa
saliva
specimen
test
respiratori
viru
neg
nicu
visit
restrict
durat
reduc
infect
control
measur
reinforc
healthcar
staff
infant
famili
infect
control
group
nicu
member
includ
hand
hygien
environment
clean
increas
awar
respiratori
symptom
second
day
outbreak
palivizumab
administ
infant
nicu
npa
surveil
test
respiratori
virus
previous
describ
perform
twice
week
infant
nicu
viral
shed
durat
possibl
coinfect
could
determin
followup
continu
four
week
last
posit
sampl
identifi
rsvposit
infant
kept
isol
nicu
discharg
test
weekli
use
pcr
neg
result
achiev
longest
viral
shed
period
day
follow
day
infant
nicu
develop
symptom
suggest
rsv
infect
therefor
first
outbreak
consid
control
thirtyfour
day
index
case
new
outbreak
identifi
control
measur
reinstat
fig
fourteen
infant
rsv
identifi
respiratori
secret
tabl
palivizumab
administ
rsvpcrneg
infant
risk
factor
eight
patient
second
outbreak
attack
rate
two
death
occur
cfr
infant
prematur
receiv
mv
rsv
infect
detect
death
attribut
bacteri
sepsi
howev
rsv
could
contribut
longest
viral
shed
time
day
among
rsvposit
infant
born
prematur
less
week
gestat
tabl
mean
gestat
age
week
rang
week
mean
age
diagnosi
day
rang
day
mean
birth
weight
g
rang
g
total
infant
asymptomat
among
symptomat
infant
present
mild
upper
respiratori
symptom
cough
coryza
fever
present
bronchiol
without
need
mv
addit
requir
invas
ventilatori
support
six
infant
would
elig
brazilian
guidelin
receiv
palivizumab
outbreak
avail
data
suffici
establish
independ
risk
factor
rsv
infect
molecular
analysi
perform
rsvposit
sampl
fig
virus
isol
first
outbreak
character
rsva
type
infect
second
outbreak
caus
rsva
type
aminoacid
analysi
evidenc
characterist
genet
signatur
second
outbreak
sampl
viral
coinfect
detect
either
outbreak
best
author
knowledg
first
report
two
consecut
neonat
outbreak
caus
two
distinct
genotyp
rsv
brazil
togeth
episod
affect
infant
high
complex
nicu
occur
rsv
postpeak
period
highest
viral
circul
rate
occur
march
may
paulo
rrtpcr
assay
genet
sequenc
analysi
pivot
confirm
two
distinct
outbreak
adopt
control
measur
includ
palivizumab
preterm
infant
underli
heart
pulmonari
diseas
prone
develop
sever
symptom
infect
rsv
compar
communityacquir
infect
nosocomi
infect
associ
significantli
higher
mortal
attack
rate
among
rsv
outbreak
nicu
report
literatur
vari
attack
rate
observ
present
studi
much
higher
reach
first
outbreak
unexpectedli
reach
second
dispar
could
attribut
fact
present
patient
presum
new
genotyp
describ
none
receiv
palivizumab
onset
outbreak
absenc
protect
immun
infant
mother
could
allow
effici
viru
replic
transmiss
furthermor
emerg
genotyp
appear
fit
advantag
preced
genotyp
rsv
group
contrast
author
observ
increas
frequenc
sever
diseas
patient
group
group
develop
respiratori
failur
requir
mv
frequenc
could
explain
rel
high
mean
gestat
age
week
present
patient
although
extrem
preterm
infant
includ
five
rsvinfect
infant
requir
mv
born
prematur
less
week
reinforc
contribut
prematur
major
risk
factor
sever
rsv
infect
guidelin
use
palivizumab
outbreak
healthcar
set
small
studi
use
palivizumab
nicu
compon
outbreak
control
procedur
retriev
literatur
first
outbreak
detect
set
patient
nicu
receiv
palivizumab
palivizumab
avail
rsvneg
patient
second
outbreak
due
limit
amount
medic
avail
high
cost
although
minor
infant
strict
indic
receiv
palivizumab
author
believ
broad
prompt
administr
drug
may
contribut
time
control
low
morbiditymort
studi
popul
previou
studi
describ
cocircul
rsv
group
b
epidem
period
includ
brazilian
popul
rsva
respons
outbreak
howev
case
occur
close
unit
nevertheless
two
differ
rsva
genotyp
identifi
nicu
first
novel
genotyp
larg
duplic
amino
acid
attach
g
glycoprotein
first
report
decemb
ontario
canada
rapidli
spread
global
occurr
rsv
specif
genotyp
nosocomi
outbreak
may
mirror
circul
viru
commun
partial
demonstr
time
outbreak
respect
season
paulo
summari
earli
etiolog
diagnosi
especi
relev
antivir
therapi
isol
measur
prevent
hospit
outbreak
reduc
need
addit
diagnost
procedur
length
hospit
stay
better
understand
rsv
molecular
epidemiolog
essenti
vaccin
antivir
drug
develop
control
measur
rsv
infect
